Canopy Growth Announces Entry of Tweed Brand to German Medical Cannabis Market

Rhea-AI Summary

Canopy Growth (TSX: WEED) (NASDAQ: CGC) has launched its Tweed brand in the German medical cannabis market, introducing four new strains through a partnership with Portuguese cultivator Gro-Vida. The new offerings include Jack Herer (sativa-dominant), Balanced Caramel and Wappa (indica-prominent), and Gelato 33 (balanced hybrid).

This expansion follows the December 2024 launch of Tweed's Glitter Bomb strain in Germany through an agreement with German-based Cansativa. The company aims to provide consistent, reliable flower supply to meet growing patient demand for higher-THC genetics, leveraging both EU-based cultivators and their EU-GMP facility in Canada.

Positive

• Market expansion into German medical cannabis sector
• Strategic partnerships with EU cultivators established
• Diversification of product portfolio with 5 new strains

Negative

• None.

News Market Reaction

-6.00%

1 alert

-6.00% News Effect

On the day this news was published, CGC declined 6.00%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Four new Tweed strains available through an agreement with Portugal-based Gro-Vida

Tweed Glitter Bomb strain launched in December 2024 through an agreement with German-based Cansativa

SMITHS FALLS, ON, Feb. 27, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has officially launched its Tweed brand in the German medical cannabis market, including the availability of four new Tweed strains grown in the EU through an agreement with Gro-Vida S.A (Gro-Vida), a Portuguese medical cannabis cultivator.

Born in Canada more than a decade ago, Tweed has a proud history in both adult-use and medical markets globally. This expanded launch of the brand in Germany will provide medical patients access to Jack Herer, a new sativa-dominant strain; Balanced Caramel and Wappa, two indica-prominent strains; and Gelato 33, a balanced hybrid strain – helping meet the growing demand from patients for higher-THC genetics.¹

"As a leader in medical cannabis, Canopy Growth is expanding its German product lineup with the launch of the Tweed brand as well as new genetics to meet the growing needs of patients and healthcare practitioners," said Luc Mongeau, CEO, Canopy Growth. "Through strategic agreements with EU-based cultivators and continued supply from our EU-GMP facility in Canada, Canopy Growth is focused on delivering a consistent, reliable flower supply enabling healthcare practitioners to confidently prescribe Tweed for patients across Germany."

This builds on Tweed's initial introduction of Glitter Bomb, an indica dominant high THC strain to the German medical market earlier in December 2024 through an agreement with Cansativa GmbH (Cansativa), a vertically integrated German cannabis cultivator and distributor.

For more information, visit www.canopymedical.de

____________________________ 1 Source: Insight Health, 'Higher THC Strains Driving Growth', L12M Period Ending December 2024.

About Canopy Growth

Canopy Growth is a world leading cannabis company dedicated to unleashing the power of cannabis to improve lives.

Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with operations in Canada, Germany, Poland, and Australia.

Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA's portfolio includes ownership of Acreage Holdings, a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Brands, a leading North American edibles brand, and majority ownership of Jetty Extracts, a California-based producer of high-quality cannabis extracts and clean vape technology. 

At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer.

For more information visit www.canopygrowth.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/canopy-growth-announces-entry-of-tweed-brand-to-german-medical-cannabis-market-302386861.html

SOURCE Canopy Growth Corporation

FAQ

What new cannabis strains is Canopy Growth (CGC) introducing to the German medical market?

CGC is introducing four new Tweed strains: Jack Herer (sativa), Balanced Caramel and Wappa (indica), and Gelato 33 (hybrid), plus the previously launched Glitter Bomb strain.

Who are Canopy Growth's cultivation partners for the German medical cannabis market?

CGC has partnerships with Portuguese cultivator Gro-Vida for four strains and German-based Cansativa for the Glitter Bomb strain.

When did Canopy Growth (CGC) launch the Tweed Glitter Bomb strain in Germany?

CGC launched the Tweed Glitter Bomb strain in the German medical market in December 2024 through Cansativa.

How is Canopy Growth (CGC) ensuring medical cannabis supply in Germany?

CGC maintains supply through strategic agreements with EU-based cultivators and their EU-GMP facility in Canada.